Survey about brigatinib for ALK-positive lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial is a survey study about how brigatinib is used for people with certain advanced lung cancer. It may help doctors understand real-world treatment patterns and experiences for ALK-positive non-small cell lung cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or recurrent non-small cell lung cancer that cannot be fully removed with surgery
- Your lung cancer has an ALK fusion gene (testing showed ALK-positive)
- You have not had an allergic (hypersensitivity) reaction to brigatinib or its ingredients
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people with advanced ALK-positive lung cancer who are already taking the targeted therapy brigatinib and have a few remaining spots of cancer. It tests whether adding local treatments (like surgery, focused radiation, or ablation) to the remaining spots can improve outcomes.
This trial tests brigatinib, a targeted pill medicine, in children and young adults with ALK-positive cancers (including ALCL and IMT, plus some other solid tumors). It’s designed to see how well it works and what side effects it causes in people whose tumors have a specific ALK change.
This study looks at the genetic changes in ALK-positive lung cancer over time. It is for people who have already started one of three targeted treatments (alectinib, brigatinib, or lorlatinib) and are willing to provide extra tissue or blood samples for testing.
This study looks at why some lung cancers with an ALK gene change do not respond to ALK-targeted drugs. It may help find better treatments for patients whose cancer stops responding early.
This study looks at how people with advanced ALK-positive non-small cell lung cancer (NSCLC) respond to the targeted drug lorlatinib. It aims to understand whether local treatments (like radiation or surgery) are needed during therapy. If you have this type of lung cancer and haven't had treatment yet, this study might be an option.
This trial looks at why ALK-positive lung cancer stops responding to the targeted drug lorlatinib, and what treatments might work next. It's for people whose cancer has progressed during first-line lorlatinib therapy.
Hear when a new Non-small Cell Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.